Format

Send to

Choose Destination
Vaccine. 2002 May 22;20(17-18):2166-73.

Pneumococcal polysaccharide vaccine: a systematic review of clinical effectiveness in adults.

Author information

1
Department of Public Health Medicine, Grampian Health Board, Aberdeen, UK. lorna.watson@isd.csa.scot.nhs.uk

Abstract

Pneumococcal polysaccharide vaccine is recommended in western countries for individuals at high risk of pneumococcal illness. We undertook a systematic review of randomised controlled trials of pneumococcal vaccine in adults, to determine the effects on clinical outcomes.

RESULTS:

In industrialised populations, no benefit was detected for outcomes other than pneumococcal bacteraemia, and this did not reach statistical significance. In non-industrial populations, clear benefit was demonstrated for mortality and all-cause pneumonia.

CONCLUSION:

Benefit from pneumococcal vaccination depends on the baseline risk of infection and characteristics of a given population. Evidence from randomised trials for widespread adult vaccination in industrial countries is lacking.

PMID:
12009269
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center